Revises reimbursement payments for providers using telemedicine and telehealth.
Impact
The impact of S3855 on state laws is significant, as it requires all health benefits plans, including those under Medicare and NJ FamilyCare, to align their reimbursement strategies for telemedicine and telehealth with those for in-person services. This could enhance the viability of telehealth services, encouraging more healthcare providers to offer remote consultations. Additionally, it restricts health insurers from imposing deductibles or copayments for telemedicine services that exceed those for in-person consultations, thus making it more affordable for patients to access healthcare remotely.
Summary
Senate Bill S3855 proposes revisions to reimbursement payments for healthcare services delivered via telemedicine and telehealth in New Jersey. The bill mandates that health insurance carriers provide coverage and payment for these services at a reimbursement rate equal to that of in-person consultations. This aims to address the disparities in reimbursement rates that currently exist between telehealth services and those delivered in-person, thereby promoting equity in healthcare access. The bill makes amendments to existing legislation, specifically P.L.2017, c.117, to achieve this objective and seeks immediate effect upon enactment.
Contention
While S3855 has widespread support for improving access to healthcare, there may be points of contention among stakeholders. Some may argue that the undefined terms regarding what constitutes covered services could lead to ambiguity. Opponents might express concern over potential financial implications for insurance carriers mandated to adjust their reimbursement structures. Furthermore, there might be debates concerning the quality of care delivered through telemedicine and how it measures up to traditional in-person visits, as well as the adequacy of current regulatory frameworks to govern such a shift in healthcare delivery modes.
Relating to the reimbursement and payment of claims by certain health benefit plan issuers for telemedicine medical services, teledentistry dental services, and telehealth services.
Revises telehealth and telemedicine requirements concerning adult prescription of certain Schedule II drugs for treatment of attention-deficit/hyperactivity disorder.